Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04983030 |
|
Recruitment Status :
Recruiting
First Posted : July 30, 2021
Last Update Posted : July 3, 2023
|
Sponsor:
Boris Juelg, MD PhD
Collaborators:
Janssen Pharmaceuticals
Harvard School of Public Health (HSPH)
Orlando Immunology Center
The University of Texas Health Science Center, Houston
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Boris Juelg, MD PhD, Beth Israel Deaconess Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 31, 2026 |
| Estimated Study Completion Date : | April 30, 2026 |